Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial.
Ontology highlight
SUBMITTER: Bear HD
PROVIDER: S-EPMC4624323 | biostudies-literature | 2015 Sep
REPOSITORIES: biostudies-literature
ACCESS DATA